Docoh
Loading...

GERN Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.

Company profile

Ticker
GERN
Exchange
Website
CEO
John Scarlett
Employees
Incorporated
Location
Fiscal year end
Former names
GERON CORPORATION
SEC CIK
IRS number
752287752

GERN stock data

(
)

Calendar

11 Mar 21
12 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Geron earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 9.93M 9.93M 9.93M 9.93M 9.93M 9.93M
Cash burn (monthly) 11.68M 309.92K 7.76M 6.41M 4.2M 5.55M
Cash used (since last report) 39.92M 1.06M 26.51M 21.91M 14.38M 18.99M
Cash remaining -30M 8.87M -16.59M -11.99M -4.45M -9.06M
Runway (months of cash) -2.6 28.6 -2.1 -1.9 -1.1 -1.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Spiegel Robert J. Common Stock Grant Aquire A No No 0 4,549 0 119,497
2 Feb 21 Aleksandra Rizo Employee Stock Option Common Stock Grant Aquire A No No 2.055 300,000 616.5K 300,000
2 Feb 21 Andrew J Grethlein Employee Stock Option Common Stock Grant Aquire A No No 2.055 300,000 616.5K 300,000
2 Feb 21 Anil Kapur Employee Stock Option Common Stock Grant Aquire A No No 2.055 300,000 616.5K 300,000
2 Feb 21 Melissa Kelly Behrs Employee Stock Option Common Stock Grant Aquire A No No 2.055 300,000 616.5K 300,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

55.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 151 152 -0.7%
Opened positions 15 27 -44.4%
Closed positions 16 16
Increased positions 54 55 -1.8%
Reduced positions 36 23 +56.5%
13F shares
Current Prev Q Change
Total value 361.54M 950.72M -62.0%
Total shares 175.39M 172.34M +1.8%
Total puts 486.3K 507.7K -4.2%
Total calls 899.5K 609.4K +47.6%
Total put/call ratio 0.5 0.8 -35.1%
Largest owners
Shares Value Change
Ra Capital Management 30.13M $47.9M 0.0%
BLK Blackrock 25.02M $39.79M +1.8%
EcoR1 Capital 18.94M $30.11M -1.5%
Vanguard 16.19M $25.74M +2.9%
STT State Street 13.56M $21.56M +16.4%
Perceptive Advisors 13.46M $21.4M 0.0%
NEA Management 13.46M $21.4M 0.0%
Great Point Partners 5.06M $8.04M -47.8%
Geode Capital Management 4.56M $7.25M +0.2%
FMR 4.11M $6.54M -15.4%
Largest transactions
Shares Bought/sold Change
Great Point Partners 5.06M -4.63M -47.8%
Millennium Management 3.12M +2.37M +315.4%
STT State Street 13.56M +1.91M +16.4%
Two Sigma Advisers 2.04M +1.01M +98.1%
SG Americas Securities 0 -1.01M EXIT
Renaissance Technologies 982.5K +961.62K +4606.4%
MS Morgan Stanley 1M +900.03K +885.4%
FMR 4.11M -747.95K -15.4%
D. E. Shaw & Co. 1.02M +678.47K +197.2%
Alps Advisors 561.17K +561.17K NEW
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abbreviated, absenteeism, accidental, accrual, Actuate, add, Aid, aimed, allele, anesthesiologist, annum, apparent, arisen, ASA, Ascentage, Astex, attached, AXL, bankruptcy, begun, bemcentinib, BerGenBio, Biden, bifurcated, biomarker, Biomedicine, BioTime, bound, Canada, cedazuridine, chance, CJEU, Commissioner, Compelling, competitor, complaint, conducive, confidence, contact, Council, County, covenant, CPRA, criterion, customarily, Dear, debarred, deceptive, deciliter, delta, denial, deny, depletion, deter, died, differentiate, Differentiating, disadvantage, dispose, disqualified, distancing, Distinguishing, divestiture, drawdown, drew, driven, driver, dual, EC, EEA, equitable, Equivalence, equivalent, exemplify, explicit, FDASIA, floating, fluidity, fundamental, fundamentally, Galecto, GCP, GMP, Governor, harbor, Hb, headache, hearing, histology, Hy, hybrid, Imago, IMpactMF, inconsistent, indirect, Inqovi, insolvency, inventor, invoice, Justice, Karyopharm, lawfully, leave, legislature, lending, lifted, lifting, line, Lixte, longest, MAA, Mateo, mental, misconduct, misrepresentation, misrepresentative, missed, momentum, monthly, motion, mutation, NaN, NCE, negligent, negligible, nonprovisional, nuclear, nurse, Orange, outreach, outsource, pace, paramount, parsaclisib, pediatric, pelabresib, penalized, persist, persuade, pharmacy, pledge, postponement, prematurely, prepay, prepayment, prime, proactively, RA, RCMD, redemption, reexamining, refinancing, regimen, remote, remotely, removed, removing, repay, repayment, rescinded, restitution, seized, Selinexor, shareholder, shelter, shut, Silicon, slowdown, slower, SPC, Speed, spliceosome, split, spring, steep, subpopulation, summer, SVB, Switching, Switzerland, telecommute, temporarily, tenant, TIc, tie, Tranche, triple, unabated, unamortized, unavoidable, underwriting, underwritten, unfair, unlawful, unmanaged, unnecessarily, unpaid, unreliable, Urgent, usage, vaccine, VAF, Valley, variant, version, vision, Wall, Warp, weeksd, XPOVIO
Removed: al, assign, ASX, bill, Bipartisan, Bulletin, circumvent, close, computed, Cooley, correlating, correspondingly, DBA, decided, digit, discover, diverse, diversify, enactment, examined, feasible, feedback, fibrotic, Hereditary, hTR, inappropriate, instability, InterMune, interpreting, involuntary, Litig, loosen, merit, metabolite, occupy, oversee, patentee, pathway, personally, preempted, proceed, Promega, promptly, pulmonology, reached, repurchased, restriction, RNAi, SDX, suit, supplemental, ticker, tiered, unanticipated, unaudited, universal, weakened